Intravenous Metoclopramide Versus Intravenous Acetaminophen for Acute Concussion Treatment (IMPACT)
A Randomized Study of Intravenous Metoclopramide Versus Intravenous Acetaminophen for Acute Concussion Treatment
The IMPACT study is a randomized, double-blind clinical trial evaluating two commonly used intravenous medications - metoclopramide and acetaminophen - for treating acute post-concussion symptoms in emergency department patients after mild head injury. The study aims to determine which treatment more effectively improves symptoms such as headache, dizziness, nausea, concentration difficulties, and emotional changes within the first week after injury.
Participants will be enrolled across two Montefiore emergency departments and followed using a validated post-concussion symptom questionnaire. Findings from this study may help improve evidence-based treatment strategies for patients experiencing concussion-related symptoms after head trauma.
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
Nearly 1.5 million patients present to US emergency departments (ED) annually following head trauma. Many, even with a low velocity mechanism of injury, report a variety of post-concussion symptoms, including headache, dizziness, and nausea. For most patients, post-concussion symptoms will resolve after several days, though up to 1/4 will develop persistent symptomatology that can last months or years.
Very few randomized studies are available to guide treatment of acute post-concussion symptoms. In the absence of evidence, most emergency physicians treat post-concussion symptoms using typical medications for the symptom - thus headache is treated with analgesic medication, nausea with antiemetics, and dizziness with medications such as meclizine. Other symptoms commonly described as part of post-concussion syndrome, such as fatigue, irritability, and poor concentration, are usually left untreated.
Two randomized studies among ED patients who experienced head trauma were recently completed at Montefiore EDs. In the first, one dose of IV metoclopramide, when compared to placebo, improved post-concussion syndrome both in the ED and one week later. In this study, IV metoclopramide was effective against a broad range of symptoms beyond just headache and nausea. Variables related to concentration (including concentration, remembering, and feeling like one is in a fog) were better in the metoclopramide arm at both one hour and at one week. Similarly, variables related to emotion (including feeling more emotional, irritability and sadness) were better in the active group. In the second study, adding IV dexamethasone to metoclopramide did not result in increased or prolonged efficacy.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 4
Contactos e Locais
Contato de estudo
- Nome: Hamed Sarikhani, MD
- Número de telefone: 929-731-2137
- E-mail: hsarikhani@montefiore.org
Estude backup de contato
- Nome: Benjamin W W.Friedman, MD,MS
- Número de telefone: 7189043333
- E-mail: befriedman@montefiore.org
Locais de estudo
-
-
New York
-
New York, New York, Estados Unidos, 10467
- Montefiore Medical Center
-
Contato:
- Hamed Sarikhani Assistant Professor of Emergency Medicine, MD
- Número de telefone: 929-731-2137
- E-mail: hsarikhani@montefiore.org
-
Contato:
- Benjamin W.Friedman, MD,MS
- Número de telefone: 718-904-3333
- E-mail: befriedman@montefiore.org
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Adults presenting to one of the study emergency departments (EDs)
- Acute minor traumatic brain injury/concussion as defined by the Zurich Consensus Statement, including symptoms in somatic, cognitive, emotional, behavioral, physical, cognitive impairment, or sleep domains
- ED visit occurring within 7 days of the head injury
- Overall pain intensity greater than >=6 on a 0-10 scale
- Rivermead Post-Concussion Questionnaire (RPQ) score of at least 10
- Reported post-concussion symptoms were not present prior to the injury
- Treating attending physician plans to administer a parenteral medication
Exclusion Criteria:
- Already treated with an anti-dopaminergic medication for post-concussion symptoms
- Contraindications to study medications, including:
- Pheochromocytoma
- Seizure disorder
- Parkinson's disease
- Use of monoamine oxidase (MAO) inhibitors
- Use of anti-rejection transplant medications
- Pregnant patients will not be excluded because both acetaminophen and metoclopramide are commonly used during pregnancy.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: Metoclopramide 10 mg
Metoclopramide 10 mg IV over 15 minutes
|
Intravenous drip
|
|
Comparador Ativo: Acetaminophen
1000 Mg IV over 15 minutes
|
Intravenous drip over 15 minutes
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Rivermead Post-Concussion Symptoms Questionnaire (RPQ) score
Prazo: From baseline to 48 hours post-treatment
|
Change in post-concussion symptoms from baseline to 48 hours after treatment will be measured using the RPQ.
The RPQ is a validated instrument designed to quantify the severity of post-concussive symptoms following mild traumatic brain injury.
It consists of 16 items encompassing physical (e.g., headache, dizziness), cognitive (e.g., poor concentration, forgetfulness), and emotional (e.g., irritability, depression) domains, each rated on a 5-point Likert scale from 0 ("Not experienced at all") to 4 ("A severe problem"), for an overall possible range of 0-64, such that higher scores reflect worsening concussive symptomatology.
Absolute change from baseline scores will be summarized by study arm using descriptive statistics.
For patients requiring rescue therapy in the ED, the pre-rescue medication RPQ score will be used in lieu of the 48-hour score to ensure that the 48-hour outcome reflects the individual's poor response to the investigational medication.
|
From baseline to 48 hours post-treatment
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in RPQ score Improvement in post-concussion symptoms measured using the RPQ between baseline and 1 hour after treatment.
Prazo: From baseline to 1 hour and 7 days post-treatment
|
Change in post-concussion symptoms will also be measured at 1 hour and 7 days post-treatment using the RPQ.
The RPQ is a validated instrument designed to quantify the severity of post-concussive symptoms following mild traumatic brain injury.
It consists of 16 items encompassing physical (e.g., headache, dizziness), cognitive (e.g., poor concentration, forgetfulness), and emotional (e.g., irritability, depression) domains, each rated on a 5-point Likert scale from 0 ("Not experienced at all") to 4 ("A severe problem"), for an overall possible range of 0-64, such that higher scores reflect worsening concussive symptomatology.
For purposes of this study, an absolute change from baseline score will be reported for the 1 hour and 7 days post-treatment timepoints.
Values will be summarized by study arm using descriptive statistics.
|
From baseline to 1 hour and 7 days post-treatment
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Numerical Rating Scale (NRS) pain score
Prazo: From baseline to 7 days post-treatment
|
Change in pain score from baseline to 7 days post-treatment will be assessed using the NRS for pain.
The NRS is a commonly used rating scale for pain in ED studies and is comprised of a segmented, 11-point assessment wherein patients verbally identify their pain severity on a scale ranging from 0 ("No pain") to 10 ("Worst pain imaginable"), such that higher scores are indicative of increased pain intensity.
For purposes of this outcome, a relative change from baseline score will be reported for the 7-day post-treatment timepoint.
Values will be summarized by study arm using descriptive statistics.
Changes in pain scores will be analyzed in relation to RPQ symptom improvement as an exploratory outcome.
|
From baseline to 7 days post-treatment
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Benjamin W Friedman, MD,MS, Montefiore Medical Center
Publicações e links úteis
Publicações Gerais
- Blyth BJ, Bazarian JJ. Traumatic alterations in consciousness: traumatic brain injury. Emerg Med Clin North Am. 2010 Aug;28(3):571-94. doi: 10.1016/j.emc.2010.03.003.
- Larsen EL, Ashina H, Iljazi A, Al-Khazali HM, Seem K, Ashina M, Ashina S, Schytz HW. Acute and preventive pharmacological treatment of post-traumatic headache: a systematic review. J Headache Pain. 2019 Oct 21;20(1):98. doi: 10.1186/s10194-019-1051-7.
- McCrory P, Meeuwisse WH, Aubry M, Cantu B, Dvorak J, Echemendia RJ, Engebretsen L, Johnston K, Kutcher JS, Raftery M, Sills A, Benson BW, Davis GA, Ellenbogen RG, Guskiewicz K, Herring SA, Iverson GL, Jordan BD, Kissick J, McCrea M, McIntosh AS, Maddocks D, Makdissi M, Purcell L, Putukian M, Schneider K, Tator CH, Turner M. Consensus statement on concussion in sport: the 4th International Conference on Concussion in Sport held in Zurich, November 2012. Br J Sports Med. 2013 Apr;47(5):250-8. doi: 10.1136/bjsports-2013-092313. No abstract available.
- Evans RW. The Postconcussion Syndrome and Posttraumatic Headaches in Civilians, Soldiers, and Athletes. Neurol Clin. 2024 May;42(2):341-373. doi: 10.1016/j.ncl.2023.12.001. Epub 2024 Jan 16.
- Friedman BW, Irizarry E, Cain D, Caradonna A, Minen MT, Solorzano C, Zias E, Zybert D, McGregor M, Bijur PE, Gallagher EJ. Randomized Study of Metoclopramide Plus Diphenhydramine for Acute Posttraumatic Headache. Neurology. 2021 May 4;96(18):e2323-e2331. doi: 10.1212/WNL.0000000000011822. Epub 2021 Mar 24.
- Barlow KM. Post-traumatic headache: An unmet medical need. Headache. 2021 Nov;61(10):1465-1466. doi: 10.1111/head.14241. No abstract available.
- Fanciullacci M, Alessandri M, Del Rosso A. Dopamine involvement in the migraine attack. Funct Neurol. 2000;15 Suppl 3:171-81.
- Charbit AR, Akerman S, Goadsby PJ. Dopamine: what's new in migraine? Curr Opin Neurol. 2010 Jun;23(3):275-81. doi: 10.1097/WCO.0b013e3283378d5c.
- Varner C, Thompson C, de Wit K, Borgundvaag B, Houston R, McLeod S. Predictors of persistent concussion symptoms in adults with acute mild traumatic brain injury presenting to the emergency department. CJEM. 2021 May;23(3):365-373. doi: 10.1007/s43678-020-00076-6. Epub 2021 Feb 8.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Lesões Cerebrais Traumáticas
- Doenças Cerebrais
- Doenças do Sistema Nervoso Central
- Doenças do Sistema Nervoso
- Ferimentos e Lesões
- Trauma, Sistema Nervoso
- Traumatismos na Cabeça, Fechado
- Ferimentos Não Penetrantes
- Lesões cerebrais
- Concussão cerebral
- Síndrome pós-concussão
- Trauma Craniocerebral
- Produtos químicos orgânicos
- Hidrocarbonetos
- Hidrocarbonetos, cíclicos
- Ácidos carboxílicos
- Ácidos hidroxi
- Hidrocarbonetos, aromáticos
- Anilides
- Amidas
- Compostos de anilina
- Aminas
- Acetanilidas
- Fenóis
- Derivados de benzeno
- Ácidos, carbocíclicos
- para-aminobenzóatos
- Aminobenzoates
- Benzoates
- Hidroxibenzoatos
- Éteres fenil
- Benzamides
- Clorobenzoatos
- Éteres de hidroxibenzoato
- Paracetamol
- Metoclopramida
Outros números de identificação do estudo
- 2025-17404
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .